Hyperreactio luteinalis in association with multiple foetal malformations – a consequence of supra-physiological HCG?

2014 ◽  
Vol 3 (1) ◽  
Author(s):  
Majed Faden ◽  
Amir H. Salehi ◽  
Jeannine Simon ◽  
Moy Fong Chen ◽  
Atilla Omeroglu ◽  
...  

AbstractHyperreactio luteinalis (HL) is characterised by ovarian cystic enlargement that is associated with high levels of human chorionic gonadotropin (hCG). Here the possible effects of abnormally high hCG levels on foetal development are demonstrated.We report a 28-year-old patient who was referred for evaluation of bilateral maternal ovarian enlargement in the second trimester. Abnormally elevated hCG (887,514 IU/L) was found with ultrasound examination identifying various foetal malformations. The karyotype was normal. Spontaneous abortion occurred at 20 weeks. Autopsy showed testicular hypertrophy with marked Leydig cell hyperplasia. The HL resolved with normalisation of the hCG levels following delivery.HL is a rare finding in normal pregnancies; the potential effects of abnormally elevated hCG on the foetus are discussed.

Author(s):  
S. L. Asa ◽  
T. A. Bayley ◽  
E. Horvath ◽  
K. Kovacs

Leydig cell clusters in the adult human testis are known to enlarge during chronic stimulation with excess LH as in Klinefelter's syndrome or following administration of exogenous human chorionic gonadotropin (hCG). However, the ultrastructural features of this hyperplasia, to our knowledge, have not been reported in association with testicular neoplasms producing hCG.We report the case of a 21-year-old man who sought medical attention because of gynecomastia. Laboratory investigation revealed a marked increase in serum hCG and elevated a-fetoprotein. A testicular mass was palpable on examination and the patient underwent orchiectomy.


2010 ◽  
Vol 134 (11) ◽  
pp. 1685-1691
Author(s):  
Glenn E. Palomaki ◽  
George J. Knight ◽  
Geralyn Lambert-Messerlian ◽  
Jacob A. Canick ◽  
James E. Haddow

Abstract Context.—We initiated a voluntary, self-funded interlaboratory comparison program in the fall of 2005 because no proficiency testing program was available to laboratories in North America offering first-trimester, combined serum and ultrasound, Down syndrome screening. Objectives.—To evaluate the first 4 years of the interlaboratory comparison program against stated goals, to identify areas of concern, and to create new initiatives as indicated. Design.—Five serum samples are distributed 3 times a year to be tested for pregnancy-associated plasma protein A, human chorionic gonadotropin or its β subunit, and dimeric inhibin-A; participants convert these results into multiples of the median. Patient histories include nuchal translucency information that enables the calculation of the risk of Down syndrome. Also included are educational components linked to interlaboratory comparison program results. Assessment of integrated (first- and second-trimester markers) risks is accomplished by having participants combine interlaboratory comparison program results with their results from a second-trimester proficiency testing program administered by the College of American Pathologists. Results.—The precision profile for pregnancy-associated plasma protein A shows decreasing coefficients of variation with increasing pregnancy-associated plasma protein A concentrations and multiples of the median (25% to 11% and 30% to 15%, respectively). In contrast, coefficients of variation are a relatively constant 12% throughout the entire range of human chorionic gonadotropin results. On a logarithmic scale, the median coefficient of variation of the risk of Down syndrome is 9%. Conclusions.—Participants in the interlaboratory comparison program reliably measure analytes, compute multiples of the median, and calculate consistent Down syndrome risks. Assays for the measurement of pregnancy-associated plasma protein A are not standardized and are less precise than those for human chorionic gonadotropin. Participants calculate reliable median equations given sonographer-specific sets of paired crown-rump length and nuchal translucency measurements.


Author(s):  
D. Ware Branch

For most women, pregnancy is suspected when the symptoms of early pregnancy develop—these include breast soreness or tenderness, fatigue, nausea, and missed menses. Human chorionic gonadotropin (hCG) is first detectable using sensitive tests in the urine and blood of pregnant women 8–10 days after conception (day 22–24 of a 28-day menstrual cycle). Concentrations of hCG rise rapidly in early pregnancy, peak at 9–10 weeks, and decline thereafter to a nadir at 20 weeks. Understanding embryo-foetal development and maternal physiological accommodation to pregnancy is required for the optimal management of pregnancy in women with autoimmune diseases. This chapter reviews the important developmental and physiologic aspects of normal pregnancy and both common and unique obstetric complications associated with selected rheumatic conditions.


2002 ◽  
Vol 48 (2) ◽  
pp. 386-388 ◽  
Author(s):  
Yoko Ohashi ◽  
Norio Miharu ◽  
Hiroshi Honda ◽  
Osamu Samura ◽  
Koso Ohama

Sign in / Sign up

Export Citation Format

Share Document